Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival

Table 4 Univariate and multivariate predictors of immune checkpoint inhibitor-mediated colitis among patients using immune checkpoint inhibitor (n = 128)

Clinical variables	Univariate predictors			Multivariate predictors
	OR	95%CI	P value	OR		95%CI	P value
Demographics
Age (yr)	1.01	0.98-1.04	0.417
Male	1.00	0.50-2.02	1.000
Female	1.00	0.50-2.02	1.000
Race
White	1.21	0.51-2.88	0.661
Black	1.00	0.14-7.33	1.000
Asian	0.79	0.20-3.07	0.730
Other	0.84	0.27-2.66	0.770
Type of malignancy
Melanoma	1.00	0.50-2.00	1.000
RCC	1.16	0.40-3.42	0.784
NSCLC	1.00	0.30-3.28	1.000
Sarcoma	0.82	0.24-2.83	0.753
Head and neck SCC	0.74	0.16-3.44	0.698
Other	1.15	0.41-3.18	0.795
Stage IV malignancy	0.72	0.24-2.22	0.572
Type of Immune Checkpoint Inhibitor
Ipilimumab plus nivolumab	1.00	0.49-2.05	1.000
Ipilimumab	1.00	0.40-2.51	1.000
Nivolumab	1.00	0.30-3.28	1.000
Pembrolizumab	1.00	0.47-2.13	1.000
Atezolizumab	1.00	0.24-4.18	1.000
Number of Infusionsa	0.98	0.93-1.02	0.273
Dose of ICI (mg/kg)	1.23	0.82-1.84	0.327
Medical History
Non-liver, non-upper GIb	2.11	0.89-5.03	0.091
Autoimmune diseaseb	2.45	1.04-5.78	0.040	1.87	0.74-4.74		0.186
Prior irAE	7.74	0.92-64.82	0.059
Family history of autoimmune diseaseb	4.43	0.90-21.74	0.067	3.98	0.74-21.38		0.107
Prior immune-enhancing therapyb	0.20	0.04-0.95	0.043	0.19	0.04-1.01		0.052
Prior interferon-γ therapy	0.15	0.018-1.31	0.087
Vitamin D use	2.51	1.14-5.54	0.022	2.48	1.01-6.07		0.047
Smoking (current or prior)	1.37	0.68-2.74	0.377
NSAID use	0.89	0.35-2.28	0.811
Any vaccine	0.49	0.20-1.21	0.123
Flu vaccine	0.53	0.19-1.45	0.219
Pneumonia vaccine	0.54	0.15-1.95	0.350
Other vaccine	1.00	0.06-16.34	1.000
Weight at start of ICI (kg)	1.01	0.99-1.03	0.393

^aNumber of infusions of immune checkpoint inhibitor prior to immune checkpoint inhibitor-mediated colitis diagnosis (cases) or total (controls).

^bSee Supplementary Table 2.

ICI: Immune checkpoint inhibitor; IMC: Immune checkpoint inhibitor-mediated colitis; RCC: Renal cell carcinoma; NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma; irAE: Immune related adverse event.